127 related articles for article (PubMed ID: 27821347)
1. New potent A
Kreft S; Bier D; Holschbach MH; Schulze A; Coenen HH
Nucl Med Biol; 2017 Jan; 44():69-77. PubMed ID: 27821347
[TBL] [Abstract][Full Text] [Related]
2. Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A
Schneider D; Oskamp A; Holschbach M; Neumaier B; Bier D; Bauer A
Nucl Med Biol; 2020; 82-83():1-8. PubMed ID: 31838339
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET.
Bauer A; Holschbach MH; Cremer M; Weber S; Boy C; Shah NJ; Olsson RA; Halling H; Coenen HH; Zilles K
J Nucl Med; 2003 Oct; 44(10):1682-9. PubMed ID: 14530487
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A
Holschbach MH; Bier D; Sihver W; Schulze A; Neumaier B
ChemMedChem; 2017 May; 12(10):770-784. PubMed ID: 28217962
[TBL] [Abstract][Full Text] [Related]
5. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments.
Elmenhorst D; Kroll T; Wedekind F; Weisshaupt A; Beer S; Bauer A
J Nucl Med; 2013 Aug; 54(8):1411-9. PubMed ID: 23740103
[TBL] [Abstract][Full Text] [Related]
6. 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for in vivo imaging of the A
Humpert S; Schneider D; Bier D; Schulze A; Neumaier F; Neumaier B; Holschbach M
Eur J Med Chem; 2024 May; 271():116380. PubMed ID: 38615410
[TBL] [Abstract][Full Text] [Related]
7. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion.
Bauer A; Langen KJ; Bidmon H; Holschbach MH; Weber S; Olsson RA; Coenen HH; Zilles K
J Nucl Med; 2005 Mar; 46(3):450-4. PubMed ID: 15750158
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the A(1)1 adenosine receptor positron emission tomography ligand [18F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX) in rodents and humans.
Bier D; Holschbach MH; Wutz W; Olsson RA; Coenen HH
Drug Metab Dispos; 2006 Apr; 34(4):570-6. PubMed ID: 16415116
[TBL] [Abstract][Full Text] [Related]
9. Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography.
Kroll T; Elmenhorst D; Weisshaupt A; Beer S; Bauer A
Mol Imaging Biol; 2014 Oct; 16(5):699-709. PubMed ID: 24595700
[TBL] [Abstract][Full Text] [Related]
10. Species Differences in Microsomal Metabolism of Xanthine-Derived A
Schneider D; Bier D; Holschbach M; Bauer A; Neumaier B
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803861
[TBL] [Abstract][Full Text] [Related]
11. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET.
Meyer PT; Bier D; Holschbach MH; Boy C; Olsson RA; Coenen HH; Zilles K; Bauer A
J Cereb Blood Flow Metab; 2004 Mar; 24(3):323-33. PubMed ID: 15091113
[TBL] [Abstract][Full Text] [Related]
12. Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18F-CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Bauer A
J Nucl Med; 2012 Nov; 53(11):1723-9. PubMed ID: 22966134
[TBL] [Abstract][Full Text] [Related]
13. Influence of incubation conditions on microsomal metabolism of xanthine-derived A
Schneider D; Bier D; Bauer A; Neumaier B; Holschbach M
J Pharmacol Toxicol Methods; 2019; 95():16-26. PubMed ID: 30476620
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies.
Matusch A; Meyer PT; Bier D; Holschbach MH; Woitalla D; Elmenhorst D; Winz OH; Zilles K; Bauer A
Nucl Med Biol; 2006 Oct; 33(7):891-8. PubMed ID: 17045169
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A(1) receptors in human brain and transfected CHO cells: Inhibition of [(3)H]CPFPX binding by adenosine and caffeine.
Elmenhorst D; Garibotto V; Prescher A; Bauer A
Neurosci Lett; 2011 Jan; 487(3):415-20. PubMed ID: 21056087
[TBL] [Abstract][Full Text] [Related]
16. A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET).
Holschbach MH; Fein T; Krummeich C; Lewis RG; Wutz W; Schwabe U; Unterlugauer D; Olsson RA
J Med Chem; 1998 Feb; 41(4):555-63. PubMed ID: 9484505
[TBL] [Abstract][Full Text] [Related]
17. Association of adenosine receptor gene polymorphisms and in vivo adenosine A1 receptor binding in the human brain.
Hohoff C; Garibotto V; Elmenhorst D; Baffa A; Kroll T; Hoffmann A; Schwarte K; Zhang W; Arolt V; Deckert J; Bauer A
Neuropsychopharmacology; 2014 Dec; 39(13):2989-99. PubMed ID: 24943643
[TBL] [Abstract][Full Text] [Related]
18. Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Zilles K; Bauer A
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1061-70. PubMed ID: 17242921
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET.
Herzog H; Elmenhorst D; Winz O; Bauer A
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1499-506. PubMed ID: 18373090
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging.
Holschbach MH; Olsson RA; Bier D; Wutz W; Sihver W; Schüller M; Palm B; Coenen HH
J Med Chem; 2002 Nov; 45(23):5150-6. PubMed ID: 12408725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
